Technology Profile
| Title: | IIIM-290, the CDK9/T1 Inhibitor for Metastatic Pancreatic Cancer |
| Value Proposition: | IIIM-290 is a novel cyclin-dependent kinase (CDK) inhibitor which has been devleoped to manage Metastatic Pancreatic Cancer. It will be used Orally. It is a potent inhibitor of cyclin-dependent kinases (CDKs), specifically Cdk-9/T1 with an IC₅₀ of 1.9 nM, and Cdk-2/A with an IC₅₀ of 90 nM. |
| Summary Application: | It will target the Metastatic Pancreatic Canceer. |
| Advantages: | It will be first Orally available CDK-9 inhibitor, targetting Metastatic Pancreatic Cancer. |
| Tech. Readiness Level: |
CSIR-Indian Institute of Integrative Medicine[CSIR-IIIM]
: director[at]iiim[dot]res[dot]in
:91-191-2585222
:https://iiim.res.in
: director[at]iiim[dot]res[dot]in
:91-191-2585222
:https://iiim.res.in
Industrial Applications:
Formulations [Drugs and Pharmaceuticals]
NCE [Drugs and Pharmaceuticals]
Patent(s):
US9932327